Evidence map›Paper›PMID 39764739›Full record

ArticleEmerging microbes & infections2025

Exploration of the feasibility of clinical application of phage treatment for multidrug-resistant

Xiangke Duan, Wenfeng Liu, Yanyu Xiao, Man Rao, Liyin Ji, Xiaofu Wan, Shuhong Han, Zixun Lin, Haichen Liu, Peifen Chen and 7 more

Abstract readCase Reports
In one paragraph

Article in Emerging microbes & infections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. International journal of molecular sciences · 2026
    Review
  2. From Environmental Organism to Nosocomial Threat:Antibiotics (Basel, Switzerland) · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Exploring the Association of Antimicrobial Use withInfection and drug resistance · 2025
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Xiangke DuanDepartment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, People's Republic of China.
Wenfeng LiuBGI Research, Shenzhen, People's Republic of China.
Yanyu XiaoDepartment of Clinical Laboratory, National Clinical Research Center for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, People's Republic of China.
Man RaoDepartment of Infection and Immunology, National Clinical Research Center for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, People's Republic of China.
Liyin JiDepartment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, People's Republic of China.
Xiaofu WanDepartment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, People's Republic of China.
Shuhong HanDepartment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, People's Republic of China.
Zixun LinDepartment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, People's Republic of China.
Haichen LiuBGI Research, Shenzhen, People's Republic of China.
Peifen ChenDepartment of Respiratory Medicine, National Clinical Research Center for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, People's Republic of China.
Kun QiaoDepartment of Thoracic Surgery, National Clinical Research Center for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, People's Republic of China.
Mingbin ZhengDepartment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, People's Republic of China.
Jiayin ShenDepartment of Science and Education, National Clinical Research Center for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, People's Republic of China.
Yang ZhouDepartment of Infection and Immunology, National Clinical Research Center for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, People's Republic of China.
Tetsuya AsakawaInstitute of Neurology, National Clinical Research Center for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, People's Republic of China.
Minfeng XiaoBGI Research, Shenzhen, People's Republic of China.
Hongzhou LuDepartment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BacteriophagesDrug Resistance, Multiple, BacterialPhage TherapySerratia InfectionsSerratia marcescensAnti-Bacterial AgentsHumansMaleMiddle AgedTreatment OutcomeAnti-Bacterial Agentsefficacy and safetymultidrug-resistancephage Spe5P4Phage treatmentSerratia marcescens (S. marcescens)

Identifiers

PMID39764739
PMCPMC11740298

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.